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Abstract 
Background: Clostridium difficile (C. difficile) is a spore-forming, Gram-positive rod that is known to be associated with 
antibiotic use. It is one of the leading causes of nosocomial diarrhea in the industrialized world and therefore warrants 
further study of its nature. It isn’t clear if co-infection by other organisms can affect the outcome of C. difficile infection 
(CDI).
Methods: A single center retrospective study was done and it used inclusion criteria of 18 years of age and being 
tested positive for CDI on FilmArray® multiplex gastro-intestinal (GI) panel. Exclusion criteria were a GI panel per-
formed on an outpatient basis, recurrent CDI, and the presence of end-stage renal disease, cirrhosis, or a non-GI 
infection. The stool sample for all patients were collected within 48 h of presentation to the hospital. There were 235 
of 2576 GI panels selected for a retrospective chart review based on the above criteria. Among these 235 patients, 
38 had a co-infection (CDI+ another GI infection = group A or cases) and the rest had only CDI (group B or controls). 
Group A was compared with group B for CDI severity, its response to treatment, recurrence, and length of the hospital 
stay, using 0.05 as the alpha criterion.
Results: Most patients with CDI were female and above the age of 60 years. Co infection did not increase the severity 
of CDI based both on the American College of Gastroenterology criteria (p 0.16) as well as Infectious Disease Society 
of America criteria (p 0.77). Co infection group also didn’t have significantly different CDI related treatment failure rate 
(p 0.23), or CDI recurrence rate (p 0.49). Co-infection was also not associated with lengthier hospital stay (p 0.41).
Conclusion: Our study suggests that co-infection doesn’t affect the severity of CDI or can cause treatment failures. 
Additionally, there was no significant increase in hospital stay, or increase in CDI recurrence associated with co-
infection. Therefore, if CDI is the leading clinical diagnosis and a patient is tested positive for co-infection in addition to 
CDI on FilmArray® multiplex GI panel, this co-infection shouldn’t change the management for CDI. Limitations of this 
study (including retrospective nature of the study, small sample size, single site study, not including all microbiome 
and non-inclusion of race) should also be taken into account, while considering the applicability of the results of this 
study.
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Background
Clostridium difficile infection (CDI) poses a major bur-
den on the patient and the healthcare system by increas-
ing mortality, morbidity, length of hospital stay, and costs 
[1–3]. There has been a steady increase in the incidence 
of CDI since 2000, with an associated increase in sever-
ity and poor clinical outcomes [4]. A European study 
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showed that one in ten patients with CDI were either 
transferred to the intensive care unit, underwent a colec-
tomy, or died as a result of the infection [5]. This requires 
further understanding of the pathophysiological and 
clinical aspects of CDI, which might help physicians to 
provide better care for patients with CDI, and it may also 
reduce the burden on the health care system.
Methods
A single center retrospective study was conducted at 
Saint Luke’s Hospital of Kansas City, MO—USA. Among 
the 2576 FilmArray® multiplex gastrointestinal (GI) pan-
els performed from January 1, 2015 to December 31, 
2016, 235 patients were selected for chart review based 
on the inclusion and exclusion criteria. Inclusion crite-
ria included age of 18 years or above who tested positive 
for Clostridium difficile (C. difficile) via the FilmArray® 
multiplex GI panel. Exclusion criteria included GI panel 
performed on an outpatient basis; recurrent CDI; and 
patients with end-stage renal disease (ESRD), cirrhosis or 
non-GI infection.
Selected patients’ population was divided into two 
groups. Patients who had CDI as well as another GI 
infection (co-infection) were placed into the case group 
(group A). Patients who had CDI only were placed into 
the control group (group B). Cases (co-infections or 
group A) were then compared with controls (CDI only or 
group B) to investigate the association between co-infec-
tion and CDI severity, its response to treatment, CDI 
recurrence, and length of hospital stay. The Chi-square 
test and Fisher’s exact tests were used to identify any sta-
tistical significance for severity, response to treatment, 
and CDI recurrence, with an alpha criterion of 0.05. An 
independent t-test was used to assess for any statistical 
significance in the duration of hospital stay, with 0.05 as 
the alpha criterion.
Results
Among the 235 patients selected based on the inclusion 
and exclusion criteria listed above, 93 patients (39.57%) 
were male and 142 patients (60.43%) were female. Two 
patients (0.85%) were younger than 20  years of age, 
13 patients (5.53%) were 20–29  years old, 24 patients 
(10.21%) were 30–39 years old, 19 patients (8.09%) were 
40–49  years old, 26 patients (11.06%) were 50–59  years 
old, 47 patients (20%) were 60–69  years old, and 104 
patients (44.26%) were 70 years old or above.
Among 235 patients, there were 38 cases (16.17%) and 
197 controls (83.83%). Among the 38 cases (patients with 
co-infection or group A), two patients had three infec-
tions at one time (C. difficile plus two other organisms). 
The rest had only one more infectious agent besides C. 
difficile.
The frequency of co-infection in cases was variable. 
Enteropathogenic Escherichia coli (E. coli) was the source 
of co-infection in 14 patients, norovirus in nine patients, 
Campylobacter jejuni in five patients and enterotoxigenic 
E. coli in three patients. Enteroaggregative E. coli, Salmo-
nella and sapovirus were source of co-infection in two 
patients each while enteroinvasive E. coli, Yersinia entero-
colitica and adenovirus in one patient each.
There was no statistically significant difference in the 
severity of CDI between the two groups based on the 
American College of Gastroenterology (ACG) criteria 
(p 0.16) as well as Infectious Disease Society of America 
(IDSA) criteria (p 0.77) as shown in Figs. 1 and 2. There 
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Fig. 1 Severity based on the criteria of American College of Gastroenterology (p-value = 0.16)
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was no significant difference in treatment failure/escala-
tion either between the two groups (p 0.23) as shown in 
Fig. 3.  
After enteropathogenic E. coli,  norovirus was the 
most common co-infection in this study. Its sub-set 
analysis showed that among the nine patients with 
norovirus co-infection, six were male and three were 
women. Only two patients were below 60 years of age. 
One patient with norovirus co-infection had severe 
infection based on both IDSA and ACG criteria while 
three other patient had severe infection based on IDSA 
criteria only. Only one out of nine patients required 
escalation of treatment. None of these nine patients 
had recurrence of CDI. Among these patients, average 
duration of hospital stay was 4.88 days, not significantly 
different than for the whole group A (cases).
Likewise, there was no significant difference in C. dif-
ficile recurrence rate between the two groups (p 0.49) as 
detailed in Fig. 4. The mean hospital stay for the patients 
in case and control groups was comparable with no sig-
nificant difference (p 0.41) between the two groups as 
show in Fig. 5.
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Fig. 2 Severity based on the criteria of Infectious Disease Society of America (p-value = 0.77)
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Fig. 3 Treatment escalation (p-value = 0.23)
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Discussion
Many studies have investigated the factors that predis-
pose patients to  CDI3 and its recurrence after the initial 
treatment [6]. Some recent studies have also investigated 
the co-infection rate with CDI [7–9]. According to a mul-
ticenter evaluation of the BioFire FilmArray® GI panel 
for etiologic diagnosis of infectious gastroenteritis [9], 
at least one potential pathogen was detected in 53.5% of 
the stool specimens that were collected, and among the 
positive samples, 31.5% tested positive for more than one 
potential pathogen. The samples that were co-infected 
showed that CDI was present in 53.4% of them. Some 
studies on pediatric population reported that CDI and 
co-infection are associated with increased severity [10]. 
However, only a few studies on adult populations have 
assessed the effects of co-infection on the severity of CDI 
[10, 11] and other clinical outcomes [12].
Our study aimed to determine the burden and effects of 
co-infection on CDI including CDI severity, its response 
to treatment, CDI recurrence, and length of the hospital 
stay in adult population.
We followed both ACG as well as IDSA criteria to 
define the severity of CDI. This included a serum albu-
min < 3.0  g/dL plus either a white blood cell (WBC) 
count ≥ 15,000  cells/mm3 or abdominal tenderness 
for ACG severity criteria. Severity of CDI based on 
the IDSA criteria was leukocytosis with a WBC count 
> 15,000 cells/mm3 or a serum creatinine level ≥ 1.5 times 
the premorbid level. Failure to respond to initial treat-
ment was determined as any step up in the treatment 
regimen. For example; if a patient was started on intra-
venous or oral metronidazole with no improvement of 
symptoms and therefore was switched to oral vancomy-
cin, was considered to be a failure of the initial treatment. 
Similarly, patients requiring increase of vancomycin dose 
or switch of oral vancomycin to oral fidaxomicin was 
considered to be treatment failure or treatment escala-
tion. Recurrence of CDI was defined as reappearance of 
symptoms and being tested positive for CDI after a com-
plete recovery of diarrhea for at least two weeks. Dura-
tion of hospital stay was measured in days for all patients 
and was compared in both groups.
The idea behind using both the ACG and IDSA crite-
ria to define severity was to allow the results to be inter-
preted in a more universal or generalized manner. We 
also minimized the confounding variables as much as 
possible. For example, in cirrhosis, albumin levels are 
low and this affects the interpretation of severity based 
on the ACG criteria. Thus, these patients were excluded. 
Similarly, creatinine in patients with ESRD has less 
meaning, but creatinine is part of the IDSA criteria for 
severity. Thus, these patients were also excluded. Patients 
with a concomitant non-GI infection were also excluded 
because they cause an independent increase in the WBC 
count and the WBC count is part of the severity criteria 
for both ACG and IDSA. Recurrent CDI is more chal-
lenging to treat than the initial CDI [13]. Therefore, if a 
patient with a recurrent CDI was to be compared to a 
patient with an initial CDI, the treatment for the recur-
rent CDI would be more likely to fail and these patients 
are expected to have a longer duration of hospital stay, 
regardless of the presence of a co-infection, compared 
with patients with an initial infection. To eliminate this 
bias/confounding factor, all patients with recurrent CDI 
were excluded and only patients with an initial CDI were 
included.
Surprisingly, in contrast to the previous studies, our 
results showed that co-infection in adult population 
does not affect outcomes in terms of CDI severity, its 
response to treatment, CDI recurrence, and length of 
hospital stay. Colonization with certain pathogenic bac-
teria, such as E. coli, has been demonstrated in literature 
at this point [14]. No objective data is available but it is 
a possibility that the co-infections in our study represent 
colonization or asymptomatic infections and they were 
detected because of the higher sensitivity of polymerase 
chain reactions employed by the FilmArray® multiplex 
GI panel [9]. This information can help to prevent unnec-
essary treatment escalation in CDI patients if another 
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Fig. 4 Clostridium difficile infection recurrence (p-value = 0.49)
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Fig. 5 Mean duration of hospital stay in days (p-value = 0.41)
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co-infection is detected via FilmArray® multiplex GI 
panel, especially if CDI is the leading clinical diagnosis. 
Additionally, if such patient’s CDI worsens, it is less likely 
to be the result of co-infection and an alternative cause 
should be investigated.
Conclusion
If CDI is the leading clinical diagnosis and a patient is 
tested positive for co-infection in addition to CDI on Fil-
mArray® multiplex GI panel, this co-infection shouldn’t 
change the management for CDI. Given additional limi-
tations of this study as outlined below, careful considera-
tion has to be given and further studies must be taken 
in to account for sick patients (such as patients in inten-
sive care units), patients with co-infection who are not 
improving with treatment for CDI alone and patients 
with additional co-morbidities (such as patients with 
ESRD, cirrhosis, inflammatory bowel disease, patients on 
chronic immune-suppressions or patients with human 
immunodeficiency virus).
Limitations
Although efforts were made to minimize confounding 
variables and evaluate the effects of co-infection on the 
outcomes of CDI, there are still some limitations to this 
study. This was a retrospective chart review study. So, 
randomization could not be done and only reported out-
comes were recorded. Due to our strict selection criteria, 
the sample size was reduced to 38 patients having co-
infection (cases) and therefore it didn’t include all micro-
biome. Race as demographic parameter wasn’t included. 
Events only reported to our institute were recorded as it 
was a single center study posing a risk of reporting bias.
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